Q1 FY2018 Earnings Conference Call



August 2, 2018 Santen Pharmaceutical Co., Ltd

Copyright© 2018 Santen Pharmaceutical Co., Ltd. All rights reserved.



Santen's Values and Mission Statement

Values




¹ "Exploring the secrets and mechanisms of nature in order to contribute to people's health"

Santen's original interpretation of a passage from chapter 22 of Zhongyong (The Doctrine of the Mean) by Confucius.

We think carefully about what is essential, decide clearly what we should do, and act quickly.

Mission Statement By focusing on ophthalmology, Santen develops unique scientific knowledge and organizational capabilities that contribute to the well-being of patients, their loved ones and consequently to society.

MTP2020 Fundamental Policy and Strategic Goals



Responding to the needs of patients and medical professionals worldwide, Santen will achieve reliable growth while sustainably contributing to ophthalmic treatment worldwide

Santen



Q1 FY2018 Financial Results ended June 30, 2018




Q1 FY2018 Financial Overview

Achieved revenue growth despite Japan NHI price cuts; profit lower YoY; Results in-line with annual forecast

Revenue	Higher revenue as overseas business growth offset negative impact from NHI price cuts							
	<u>56.5 bil yen</u> YoY: +1.0%							
		factor in Q1 of prior year caused lower s implemented to control SGA expenses h annual forecast						
Operating	Core basis <u>11.7 bil yen</u>	IFRS basis 10.0 bil yen						
profit	YoY: -14.8%	YoY: -16.9%						
	SGA 16.2 bil yen YoY: +7.4%							
	R&D 5.6 bil yen YoY: +0.1%							



Q1 FY2018 Revenue Overseas business continued strong growth





7

Q1 FY2018 Core Operating Profit

Cost optimization efforts reduced the negative impact from NHI price cuts; results in-line with annual forecast

	Q1 FY17				13.7	Japan bus	siness
Japan	Pharma OTC	16.0 1.8	→ 14.6 → 1.6	-8.6% -9.4%	-1.4 -0.2	Japan pharma	YoY impact from transitory revenue boost in Q1 of prior year, COGS ratio increase due to NHI price cut and product mix; SGA expenses lower with cost control efforts
	Surgical	0.1	→ 0.2	+20.6%	0.0	OTC	YoY impact with sales campaign boost in Q1 of prior year; SGA expenses lower with cost control efforts
Overso (/	Asia Currency	2.3	→ 3.3	+42.3%	0.8	Overseas I	business Higher with revenue growth and expense
		2.0	→ 1.6	-19.8%	<mark>-0.5</mark>	Asia	management Though good profit recorded in the various countries,
(EN	MEA currency impact)	2.0	110		0.1	EMEA	profit was temporarily lower, impacted by Russia which experienced demand boost in 1H of prior year
(US	-1.2	→ -0.9	-24.0%	0.3	US	Lower mainly with suspension of DE-109 U.S. market launch related expenses
HQ	HQ SGA	-2.5	→ - 2.8	+11.8%	<mark>-0.3</mark>	R&D expenses	Nearly flat on completion of DE-117 clinical trials in Japan, the suspension of DE-109 and cost optimization efforts
	R&D	-5.6	→ -5.6	+0.1%	0.0		Q1 FY17 Q1 FY18
	Other	0.8	→ -0.3		-1.1		USD JPY 111.33 JPY 108.87
	Q1 FY18				11.7 -14.8% (-2.0)		EURJPY 122.95JPY 129.57CNYJPY 16.22JPY 17.01




0.8

Q1

0.2


Performance by Business (Japan)





8




Performance by Business (Asia)















Performance by Business (EMEA)










10



FY2018 Forecast (No change from May 9)






Dividend Forecast for FY2018 (No change from May 9)

Annual Dividends

FY2018 forecast: JPY 26 / share

- Stable and sustained return to shareholders
- Mid and Long term strategic investment for the growth beyond 2020
 >>Implementing shareholder returns policy to achieve the best balance between above two priorities considering dividends and total return



The company implemented a 5-for-1 stock split on April 1, 2015. Accordingly, the calculations of annual dividend per share have been adjusted in all periods for comparison purposes. J-GAAP standards used until FY13, IFRS applied from FY14.

Status of Research & Development



Naveed Shams, M.D., Ph.D.

Senior Corporate Officer Chief Scientific Officer (CSO) Head of Global Research & Development

Pipeline / Product Development Status (1)



As of August 1, 2018

	Indication	Region	Status
		US	P2 <i>Plan: <u>2nd half FY2018 P3 start</u></i>
DE-117 EP2 receptor agonist	Glaucoma / ocular hypertension	Japan	Filed <i>Plan: 2nd half FY2018 approval</i>
		Asia	P3 Plan: 2 nd half FY2018 P3 completion
DE-126	Glaucoma /	US	Doh
FP/EP3 receptors dual agonist	ocular hypertension	Japan	P2b
DE-128	Glaucoma	US	P2/3 Plan: Calendar 2018~2019 P2/3 completion, Calendar 2020~2021 launch
InnFocus MicroShunt		Europe	CE mark granted
		US	P3 Plan: <u>2nd half FY2018 an additional clinical trial start</u>
DE-109	Uveitis	Japan	P3
IVT sirolimus		Europe	P3
		Asia	Filed
DE-122 Anti-endoglin antibody	Wet age-related macular degeneration	US	P2a Plan: Jan~Jun 2019 P2a completion

<u>Updated information is underlined.</u> See Santen Consolidated Results for more details.

Pipeline / Product Development Status (2)



	Indication	Region	Status
DE-089 Diquas	Dry eye	China	Approved Plan: FY2018 launch
DE-076B Severe keratitis in patients		Asia	Launched
ciclosporin	Cyclokat / Ikervis with dry eye	US	P2
DE-076C Vekacia / <i>Verkazia</i> ciclosporin	Vernal kerato-conjunctivits	Europe	Approved
DE-114A epinastine HCI (high dose)	Allergic conjunctivitis	Japan	<u>P3 completion</u> Plan: <u>2nd half of FY2018 filing</u>
DE-127 atropine sulfate	Муоріа	Asia	P2 Plan: 2 nd half of FY2019 P2 completion

Updated information is underlined. See Santen Consolidated Results for more details.



Appendix




Q1 FY2018 Profit and Loss Statement

	Q1 F	(17	Q1 F		
(JPY billions)	Actual	vs Revenue	Actual	vs Revenue	YoY
Revenue	55.9		56.5		1.0%
COGS	-21.6	-38.6%	-23.0	-40.8%	6.7%
SGA expenses	-15.1	-26.9%	-16.2	-28.6%	7.4%
R&D expenses	-5.6	-10.0%	-5.6	-9.9%	0.1%
Amortization on intangible assets assosiated with products	-1.7	-3.0%	-1.7	-3.1%	5.0%
Other income	0.1	0.1%	0.1	0.2%	42.9%
Other expenses	-0.1	-0.1%	-0.0	-0.1%	-52.4%
Operating profit (IFRS)	12.1	21.5%	10.0	17.7%	-16.9%
Finance income	0.5	0.8%	0.5	0.9%	10.8%
Finance expenses	-0.4	-0.8%	-1.1	-1.9%	149.6%
Profit before tax	12.1	21.6%	9.5	16.7%	-21.7%
Income tax expenses	-3.1	-5.5%	-2.6	-4.6%	-15.2%
Actual tax ratio	25.4%		27.5%		2.1pt
Net profit (IFRS)	9.0	16.1%	6.9	12.1%	-24.0%
Core operating profit	13.7	24.5%	11.7	20.7%	-14.8%
Core net profit	10.2	18.2%	8.6	15.3%	-15.1%



Q1 FY2018 Financial Position



	March 31, 2018	June 30, 2018	Change
Non-current assets	205.1	204.0	-1.1
Property, plant and equipment	29.7	30.6	0.9
Intangible assets	134.5	134.8	0.3
Financial assets	35.8	34.1	-1.7
Other	5.1	4.4	-0.7
Current assets	183.4	174.4	-8.9
Inventories	30.6	31.8	1.2
Trade and other receivables	78.7	80.6	1.9
Cash and cash equivalents	69.3	57.5	-11.8
Other	4.8	4.6	-0.2
Equity	287.6	289.3	1.7
Non-current liabilities	38.7	40.5	1.8
Financial liabilities	3.5	3.5	-
Long-term liabilities	17.7	18.6	0.9
Deferred tax liabilities	12.9	13.6	0.7
Other	4.6	4.9	0.2
Current liabilities	62.2	48.7	-13.6
Trade and other liabilities	29.7	27.1	-2.6
Other financial liabilities	14.4	11.5	-2.9
Income tax payable	7.7	2.3	-5.4
Other	10.4	7.8	-2.6



Q1 FY2018 Segment Revenue

	Japan			Overseas			Total		
(JPY billions)	Q1 FY2017	Q1 FY2018	YoY	Q1 FY2017	Q1 FY2018	YoY	Q1 FY2017	Q1 FY2018	YoY
Pharamaceuticals	39.7	38.0	-4.1%	16.3	18.4	13.3%	55.9	56.5	1.0%
Prescription	35.0	33.7	-3.8%	16.2	18.3	13.1%	51.2	52.0	1.6%
Ophthalmic	34.9	33.6	-3.6%	16.1	18.2	13.5%	50.9	51.9	1.8%
Others	0.2	0.1	-52.3%	0.1	0.1	-32.4%	0.3	0.2	-43.0%
OTC	3.9	3.5	-11.8%	0.1	0.1	-2.2%	4.0	3.5	-11.7%
Medical devices	0.6	0.6	5.6%	0.0	0.0	340.4%	0.6	0.7	8.3%
Others	0.1	0.2	107.1%	0.0	0.0	626.3%	0.1	0.3	126.6%
Sales ratio	70.9%	67.4%		29.1%	32.6%				

Segment Revenue



Capital Expenditures / Depreciation & Amortization

	FY20)17	F		
	Q1	Full year	Q1		Full year
(JPY billions)	Actual	Actual	Actual	YoY	Forecast
Capital expenditures	1.0	5.4	1.3	31.4%	7.5
Depreciation and amortization*	1.0	4.2	1.0	-0.2%	4.3
Amortization on intangible assets associated with products	1.7	6.7	1.7	5.0%	6.9
Intangible assets -Merck products	1.4	5.6	1.5	5.2%	5.8
Intangible assets -Ikervis	0.2	0.7	0.2	5.2%	0.7

*Excludes amortization on intangible assets associated with products and long-term prepaid expenses



Prescription Ophthalmic Market in Japan

	Q1 FY2017							Q1 FY2018						
	Santen*		Market		Santen		Santen*		Market		Santen			
(JPY billions)	Value	Change (YoY)	Value	Change (YoY)	market share*		Value	Change (YoY)	Value	Change (YoY)	market share*			
Total	41.4	6.5%	90.4	4.3%	45.8%	#1	42.9	3.6%	91.7	1.5%	46.8%	#1		
Glaucoma	9.2	-2.2%	29.3	0.5%	31.4%	#1	8.9	-3.6%	28.7	-1.9%	30.9%	#1		
Anti-VEGF	15.1	14.6%	21.1	14.1%	71.5%	#1	16.8	11.1%	23.3	10.2%	72.1%	#1		
Corneal/dry eye	7.3	3.0%	11.7	3.5%	62.5%	#1	7.0	-4.3%	11.4	-3.2%	61.7%	#1		
Allergy	4.1	20.9%	8.9	8.8%	46.4%	#1	5.1	22.9%	10.0	13.1%	50.4%	#1		
Anti-infection	1.5	-13.0%	3.7	-4.2%	41.3%	#1	1.3	-18.3%	3.4	-7.1%	36.4%	#1		

		Jul	1, 2017	- Jun 30, 2	018	
	Sa	nten*	Ma	rket	Santen	
	Value	Change (YoY)	Value	Change (YoY)	market share*	
Total	169.4	6.0%	364.6	4.4%	46.5%	#1
Glaucoma	35.6	-2.8%	114.4	-0.1%	31.1%	#1
Anti-VEGF	62.9	12.6%	87.4	13.4%	72.0%	#1
Corneal/dry eye	28.7	-0.1%	46.3	0.8%	62.0%	#1
Allergy	21.5	26.9%	44.0	14.4%	48.7%	#1
Anti-infection	5.3	-14.7%	13.6	-5.4%	38.8%	#1



Forward-Looking Statements

- Information given in this presentation contains certain forward-looking statements concerning forecasts, projections and plans whose realization is subject to risk and uncertainty from a variety of sources. Actual results may differ significantly from forecasts.
- Business performance and financial condition are subject to the effects of medical regulatory changes made by the governments of Japan and other nations concerning medical insurance, drug pricing and other systems, and to fluctuations in market variables such as interest rates and foreign exchange rates.
- The process of drug research and development from discovery to final approval and sales is long, complex and uncertain. Individual compounds are subject to a multitude of uncertainties, including the termination of clinical development at various stages and the non-approval of products after a regulatory filing has been submitted. Forecasts and projections concerning new products take into account assumptions concerning the development pipelines of other companies and any co-promotion agreements, existing or planned. The success or failure of such agreements could affect business performance and financial condition significantly.
- Business performance and financial conditions could be affected significantly by a substantial drop in sales of a major drug, either currently marketed or expected to be launched, due to termination of sales as a result of factors such as patent expiry and complications, product defects or unforeseen side effects. Santen Pharmaceutical also sells numerous products under sales and/or manufacturing license from other companies. Business performance could be affected significantly by changes in the terms and conditions of agreements and/or the non-renewal of agreements.
- Santen Pharmaceutical is reliant on specific companies for supplies of certain raw materials used in production. Business performance could be affected significantly by the suspension or termination of supplies of such raw materials if such and event were to adversely affect supply capabilities for related final products.

